FY18 Guide & Annual Results, page-485

A big improvement in profit margin (EBITDA/REVENUE) in FY18, the company expects to improve further in FY19.

Once CFDA/SAMR approval is received within this calendar as CEO expected (source:AFR), China sales should grow substantially because Bellamy’s is known by Chinese as one of the top 3 global infant formula brands (this might be spread by Daigou, similar to high promotion of a2 by them, imo) and currently only have 13 CFDA/SAMR approved infant formula series/brands.